<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206059</url>
  </required_header>
  <id_info>
    <org_study_id>201907086</org_study_id>
    <nct_id>NCT04206059</nct_id>
  </id_info>
  <brief_title>Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine</brief_title>
  <acronym>CLASS-D</acronym>
  <official_title>Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective within-subject study of dexmedetomidine sedation paired with CLAS conditions in&#xD;
      repeated blocks. Intervention will consist of CLAS in-phase with EEG slow waves. Anti-phase&#xD;
      stimulation will serve as an active control while sham stimulation will serve as a passive&#xD;
      control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both nonpharmacologic and pharmacologic interventions augment expression of EEG slow waves&#xD;
      that mimic those of natural sleep. Closed loop auditory stimulation (CLAS) is a noninvasive&#xD;
      inexpensive approach to augment the spectral power and duration of these slow waves. Whether&#xD;
      in-phase CLAS may address this need is unknown, since acoustic potentiation of&#xD;
      pharmacologically-induced slow waves has not been investigated. This prospective&#xD;
      within-subject study of dexmedetomidine sedation paired with CLAS will assess the feasibility&#xD;
      of augmenting EEG slow waves during sedation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in EEG slow wave amplitude from sham to in-phase stimulation</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>EEG slow waves amplitude relative to the timing of the stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in EEG slow wave duration from sham to in-phase stimulation</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>EEG slow waves duration relative to the timing of the stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in EEG slow wave amplitude from anti-phase to in-phase stimulation</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>EEG slow waves amplitude relative to the timing of the stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in EEG slow wave duration from anti-phase to in-phase stimulation</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>EEG slow waves duration relative to the timing of the stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of reactivity to thermal stimulation from anti-phase to in-phase stimulation</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>Threshold for responsiveness to thermal stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of reactivity to thermal stimulation from sham to in-phase stimulation</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>Threshold for responsiveness to thermal stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in slow wave activity on the night of the intervention will be compared to that on the night prior to the study session.</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>Slow wave activity calculated during N3 sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localization of slow waves</measure>
    <time_frame>up to 3 months after consent</time_frame>
    <description>Brain regions with localization of EEG slow waves during dexmedetomidine sedation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Sleep</condition>
  <condition>Sedation Complication</condition>
  <arm_group>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation, and 0 dB stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>A non-contrast brain MRI will be acquired for localizing EEG slow waves</description>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <other_name>Structural magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative Sensory Testing (QST)</intervention_name>
    <description>Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.</description>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <other_name>Quantitative Sensory Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Home sleep study</intervention_name>
    <description>Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.</description>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <other_name>Unattended polysomnography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acoustic stimulation (65db) up-slope of EEG with QST</intervention_name>
    <description>Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves</description>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <other_name>In-phase CLAS with sensory testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acoustic stimulation (65db) down-slope of EEG with QST</intervention_name>
    <description>65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)</description>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <other_name>Anti-phase CLAS with sensory testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0 db with QST</intervention_name>
    <description>sham stimulation (0 dB volume)</description>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <other_name>Sham CLAS with sensory testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml</description>
    <arm_group_label>CLASS-D Cohort</arm_group_label>
    <other_name>Dexmedetomidine hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-40 years&#xD;
&#xD;
          -  Healthy volunteers (American Society of Anesthesiologists Physical Status 1-2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed sleep disorders&#xD;
&#xD;
          -  Habitually short sleepers&#xD;
&#xD;
          -  Diagnosed psychiatric disorders&#xD;
&#xD;
          -  Use of psychoactive medication (e.g., antidepressants, mood stabilizers or&#xD;
             antipsychotics), diagnosed hearing disorder&#xD;
&#xD;
          -  Neck circumference &gt; 40 cm&#xD;
&#xD;
          -  Body Mass Index &gt; 30&#xD;
&#xD;
          -  Acknowledged recreational drug or nicotine use&#xD;
&#xD;
          -  Resting heart rate during slow wave sleep &lt; 40 beats per minute&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Persistently inconsistent or elevated QST heat pain tolerance thresholds (&gt;50 ºC).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben J Palanca, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Guay, MD</last_name>
    <phone>314-599-2922</phone>
    <email>cguay@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine/Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Guay, MD</last_name>
      <phone>314-599-2922</phone>
      <email>cguay@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Prerau MJ, Brown RE, Bianchi MT, Ellenbogen JM, Purdon PL. Sleep Neurophysiological Dynamics Through the Lens of Multitaper Spectral Analysis. Physiology (Bethesda). 2017 Jan;32(1):60-92. Review.</citation>
    <PMID>27927806</PMID>
  </reference>
  <reference>
    <citation>Léger D, Debellemaniere E, Rabat A, Bayon V, Benchenane K, Chennaoui M. Slow-wave sleep: From the cell to the clinic. Sleep Med Rev. 2018 Oct;41:113-132. doi: 10.1016/j.smrv.2018.01.008. Epub 2018 Feb 5. Review.</citation>
    <PMID>29490885</PMID>
  </reference>
  <reference>
    <citation>Neske GT. The Slow Oscillation in Cortical and Thalamic Networks: Mechanisms and Functions. Front Neural Circuits. 2016 Jan 14;9:88. doi: 10.3389/fncir.2015.00088. eCollection 2015. Review.</citation>
    <PMID>26834569</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ben Palanca</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

